Hello JITC Readers,
Welcome to the last edition of the JITC Digest in 2023. It’s been another wonderfully successful year for the journal, one that saw the publication of more than 400 articles and the engagement of nearly 1,300 unique reviewers. Additionally, 2023 featured the completion of our special series on liquid biopsies while commencing a new collection on computational I-O. I am also extremely proud of the inaugural Peer Review Mentorship Program graduates and their mentors that helped make the experience a resounding success and paved the way for an even larger number of participants in the coming year.
Before we look ahead to 2024, I would like to highlight a few recent articles that come from across the globe and span our original research sections. A multicenter randomized phase II trial by Benedetta Pellegrino et al demonstrates the utility of subcutaneous (SC) trastuzumab as an alternative for patients with early-stage HER2-positive breast cancer. Their findings suggest that this SC approach, which is more patient friendly, may lead to improved stromal tumor infiltrating lymphocytes compared with intravenous administration.
William C. Temple and colleagues humanized previously generated anti-CD72 nanobodies from which the resulting CD72 CAR-T cells were evaluated both in vitro and in vivo against preclinical models of B cell acute lymphoblastic leukemia and B cell non-Hodgkin’s lymphoma. Describing preclinical characterization and development of a novel cellular therapy, their work also informs CAR design principles to support a future, first-in-human phase I clinical trial to evaluate humanized CD72 nanoCARs in patients with CD72+ B cell malignancies that do not respond to CD19 CAR-T cell therapy.
Check out these selections and more in the Editor Picks below. Most importantly, I wish you all a happy holiday season and best wishes in the new year!
Regards,
James L. Gulley, MD, PhD, FACP
Journal for ImmunoTherapy of Cancer Interim Editor-in-Chief
No comments:
Post a Comment